US price erosion and competitive pressure
US generic market faces low single-digit price erosion; margins remain under pressure from competition.
medium · management_commentary
Glenmark Pharmaceuticals Limited — Q2 FY25
Glenmark's Q2 FY25 consolidated revenue grew 7.1% YoY to INR 3,434 crore, driven by strong India (13.9% YoY) and Europe (14.6% YoY) performance, partially offset by a 1.2% decli...
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Monroe plant delay
Monroe plant has been non-operational; any further delay in FDA clearance could prolong the $25-26M annual cash burn.
high · analyst_questionSupply constraints for Lirafit
Lirafit (GLP-1 biosimilar) faced supply issues; resolution expected from December but could impact scaling.
medium · analyst_questionROW growth slowdown
ROW revenue declined 4.1% YoY due to high base and geopolitical challenges; full-year growth guided at high single digit.
low · data_observation